Mentor Capital (MNTR.PK) Top Gainer in Cancer Immunotherapy Index Print E-mail
Friday, 28 August 2009 12:29

SAN DIEGO--(BUSINESS WIRE)--The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009.

The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector. In this first reporting, the strong six-week CI Index gain was paced by the 78% share price improvement of Mentor Capital, Inc. (Pink Sheets: MNTR - News).

On July 10, 2009, Mentor Capital announced it had acquired a significant interest in and was a new public market proxy for Quantum Immunologics, Inc., a private company in FDA breast cancer trials. Oncothyreon (NASDAQ:ONTY - News), with significant lung cancer involvement, followed in CI Index performance with a 71% gain in its stock. Dendreon (NASDAQ:DNDN - News), with $2.7 Billion market capitalization, is the largest company in the Cancer Immunotherapy Index, and experienced a 1,000% share price gain during the Spring of 2009.

In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body's own immune system is triggered to attack cancer cells. Patients report only flu-like symptoms as their now activated natural defenses attempt to eradicate or stabilize the targeted cancers. The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 Billion.

The current combined market cap of the index component companies is $3.4 Billion. In addition to Mentor Capital, Oncothyreon and Dendreon, the CI Index features ImmunoCellular Theraputics (IMUC.OB), Antigenics (NASDAQ:AGEN - News), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX - News), Northwest Biotherapeutics (NWBO.OB), CEL - SCI Corp. (AMEX:CVM - News) and Generex Biotechnology (NASDAQ:GNBT - News) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express.

The CI Index was developed in consultation with Mike Havrilla, PhD, co-founder and Managing Editor of BioMed Reports. Dr. Havrilla actively manages 23 indexes. The Cancer Immunotherapy Index is primarily an immunotherapy subset of his Cancer Diagnostic & Therapeutic (Dx/Tx) Micro-Cap Index. Weekly detail updates of the Cancer Immunotherapy Index may be reviewed at Mentor Capital's website.

 Disclosure: Long IMUC.ob, 

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus